-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Expanding the role of cancer prevention in clinical trials design and analysis
Graham W Warren, James R Marshall
Editorial: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Blake T Aftab, Charles M Rudin
Therapeutic Perspective: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
New-generation triazole antifungal drugs: review of the Phase II and III trials
Corrado Girmenia,Erica Finolezzi
Review Article: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Brad Spellberg
Interview: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation
-
Emerging therapies for head and neck cancer: review of the Phase II and III trials
Nicole G Chau, Bonnie S Glisson
Review Article: Clinical Investigation